Abstract: The subject of the study is the excise tax on the pharmaceutical substance of ethyl alcohol, various aspects, features in the implementation of the excise tax on the pharmaceutical substance of ethyl alcohol. The purpose of the study is to analyze the excise tax on the pharmaceutical substance of ethyl alcohol, identify problems based on the analysis of the excise tax on the pharmaceutical substance of ethyl alcohol, and propose directions for the development of the excise tax on the pharmaceutical substance of ethyl alcohol for the purposes of harmonization of legislation. The author examines in detail such features of the excise tax on the pharmaceutical substance of ethyl alcohol as: lists of pharmaceutical products, the object of taxation of excise tax, the application of various rates when performing operations with the pharmaceutical substance of ethyl alcohol, the specifics of the application of deductions for this excise tax, as well as other issues. This study was conducted based on the application of general scientific research methods, including systematic, logical, comparative analysis, and the method of analogy. The main conclusions of the study are that this tax is aimed at controlling the misuse of medical alcohol in the production of alcoholic beverages, imposing excise taxes on such production in order to equalize its value. As part of the implementation of the new mechanism, pharmaceutical companies face an additional administrative burden regarding the need to confirm the intended use of the pharmaceutical substance ethyl alcohol. At the same time, the author highlights an urgent problem for the excise tax on the pharmaceutical substance of ethyl alcohol, which is an additional tax burden in the case of the purchase of more than 500,000 thousand liters of pharmaceutical substance of ethyl alcohol for the production of medicines that are not included in the lists of pharmaceutical products. The scientific novelty lies in the refinement of a new approach to state regulation of excise taxation, based on a detailed analysis of legislative norms and rules, as well as an assessment of the effects of their impact on the pharmaceutical industry.

Abstract: The subject of the study is comprehensive support tools based on the example of a SPIC, various aspects of the conclusion of a SPIC, requirements for companies when concluding a SPIC in relation to the pharmaceutical industry. The purpose of the study is to analyze complex support tools, identify problems based on the analysis of complex support tools using the example of SPIC in relation to the pharmaceutical industry. The author examines in detail such features of the SPIC as: requirements for the conclusion of a SPIC, tax and non-tax benefits when concluding a SPIC, the concepts of "obligations" in complex support tools, price regulation of medicines from the list of VED, administrative barriers, opacity of requirements for an investment project within the framework of the conclusion of a SPIC, penalties for deviations from targets, etc. other matters. This study was conducted on the basis of the application of general scientific research methods, including systematic, logical, comparative analysis, and the method of analogy. The main conclusions of the study are the relevance of comprehensive support tools, including SPIC. The SPIC is currently an important tool for comprehensive support for both the state and companies, as it offers serious tax and non-tax benefits, which has a positive effect on investment activity in the Russian Federation. At the same time, the author highlights relevant issues for the SPIC, including administrative barriers, price regulation of medicines from the list of VED, the parties with whom a potential investor concludes a SPIC, penalties. The scientific novelty lies in the analysis of problems during the conclusion of a SPIC that were not previously highlighted, including within the pharmaceutical industry, as well as the proposal of relevant directions for the development of a SPIC that can increase the attractiveness of this investment instrument.